BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 24496303)

  • 1. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients.
    Tefferi A; Guglielmelli P; Lasho TL; Rotunno G; Finke C; Mannarelli C; Belachew AA; Pancrazzi A; Wassie EA; Ketterling RP; Hanson CA; Pardanani A; Vannucchi AM
    Leukemia; 2014 Jul; 28(7):1494-500. PubMed ID: 24496303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients.
    Tefferi A; Nicolosi M; Mudireddy M; Szuber N; Finke CM; Lasho TL; Hanson CA; Ketterling RP; Pardanani A; Gangat N; Mannarelli C; Fanelli T; Guglielmelli P; Vannucchi AM
    Am J Hematol; 2018 Mar; 93(3):348-355. PubMed ID: 29164670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons.
    Tefferi A; Lasho TL; Finke CM; Knudson RA; Ketterling R; Hanson CH; Maffioli M; Caramazza D; Passamonti F; Pardanani A
    Leukemia; 2014 Jul; 28(7):1472-7. PubMed ID: 24402162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prognostic value of JAK2, MPL and CALR mutations in Chinese patients with primary myelofibrosis].
    Xu ZF; Li B; Liu JQ; Li Y; Ai XF; Zhang PH; Qin TJ; Zhang Y; Wang JY; Xu JQ; Zhang HL; Fang LW; Pan LJ; Hu NB; Qu SQ; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2016 Jul; 37(7):576-80. PubMed ID: 27535857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients.
    Guglielmelli P; Lasho TL; Rotunno G; Score J; Mannarelli C; Pancrazzi A; Biamonte F; Pardanani A; Zoi K; Reiter A; Duncombe A; Fanelli T; Pietra D; Rumi E; Finke C; Gangat N; Ketterling RP; Knudson RA; Hanson CA; Bosi A; Pereira A; Manfredini R; Cervantes F; Barosi G; Cazzola M; Cross NC; Vannucchi AM; Tefferi A
    Leukemia; 2014 Sep; 28(9):1804-10. PubMed ID: 24549259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evaluation of the prognostic value of MIPSS70-plus in Chinese patients with primary myelofibrosis].
    Yan X; Li B; Qin TJ; Qu SQ; Pan LJ; Wu JY; Liu D; Xiao ZJ; Xu ZF
    Zhonghua Xue Ye Xue Za Zhi; 2021 Jan; 42(1):15-20. PubMed ID: 33677863
    [No Abstract]   [Full Text] [Related]  

  • 7. Mutations and prognosis in primary myelofibrosis.
    Vannucchi AM; Lasho TL; Guglielmelli P; Biamonte F; Pardanani A; Pereira A; Finke C; Score J; Gangat N; Mannarelli C; Ketterling RP; Rotunno G; Knudson RA; Susini MC; Laborde RR; Spolverini A; Pancrazzi A; Pieri L; Manfredini R; Tagliafico E; Zini R; Jones A; Zoi K; Reiter A; Duncombe A; Pietra D; Rumi E; Cervantes F; Barosi G; Cazzola M; Cross NC; Tefferi A
    Leukemia; 2013 Sep; 27(9):1861-9. PubMed ID: 23619563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CALR mutation screening in pediatric primary myelofibrosis.
    An W; Wan Y; Guo Y; Chen X; Ren Y; Zhang J; Chang L; Wei W; Zhang P; Zhu X
    Pediatr Blood Cancer; 2014 Dec; 61(12):2256-62. PubMed ID: 25176567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Pathogenesis and Clinical Significance of Driver Mutations in Primary Myelofibrosis: A Review.
    Alshemmari SH; Rajan R; Emadi A
    Med Princ Pract; 2016; 25(6):501-509. PubMed ID: 27756071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2016 Dec; 91(12):1262-1271. PubMed ID: 27870387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis.
    Kim BH; Cho YU; Bae MH; Jang S; Seo EJ; Chi HS; Choi Y; Kim DY; Lee JH; Lee JH; Lee KH; Park YM; Lee JK; Park CJ
    J Korean Med Sci; 2015 Jul; 30(7):882-8. PubMed ID: 26130950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Detection of ASXL1 Mutation and CALR Mutation Coexistance in Patients with Ph Negative Myeloproliferative Neoplasm and Its Clinical Gignificance].
    Chen MY; Shen HJ; Chao HY; Zhou M; Lu XZ; Zhang XW; Liu J; Jiang NK; Wang Q
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1738-1743. PubMed ID: 29262908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2014 Sep; 89(9):915-25. PubMed ID: 25124313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis.
    Guglielmelli P; Lasho TL; Rotunno G; Mudireddy M; Mannarelli C; Nicolosi M; Pacilli A; Pardanani A; Rumi E; Rosti V; Hanson CA; Mannelli F; Ketterling RP; Gangat N; Rambaldi A; Passamonti F; Barosi G; Barbui T; Cazzola M; Vannucchi AM; Tefferi A
    J Clin Oncol; 2018 Feb; 36(4):310-318. PubMed ID: 29226763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis.
    Rozovski U; Verstovsek S; Manshouri T; Dembitz V; Bozinovic K; Newberry K; Zhang Y; Bove JE; Pierce S; Kantarjian H; Estrov Z
    Haematologica; 2017 Jan; 102(1):79-84. PubMed ID: 27686378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical and prognostic relevance of driver mutations in 203 Taiwanese patients with primary myelofibrosis.
    Kuo MC; Lin TH; Sun CF; Lin TL; Wu JH; Wang PN; Huang YJ; Chang H; Huang TY; Shih LY
    J Clin Pathol; 2018 Jun; 71(6):514-521. PubMed ID: 29203554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognosis of Primary Myelofibrosis in the Genomic Era.
    Bose P; Verstovsek S
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S105-13. PubMed ID: 27521306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calreticulin mutation profile in Indian patients with primary myelofibrosis.
    Sazawal S; Singh N; Mahapatra M; Saxena R
    Hematology; 2015 Dec; 20(10):567-70. PubMed ID: 25959795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostication in MF: from CBC to cytogenetics to molecular markers.
    Zhou A; Oh ST
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):155-64. PubMed ID: 25189726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved Survival of Calreticulin-Mutated Patients Compared With Janus Kinase 2 in Primary Myelofibrosis: A Meta-Analysis.
    Kourie HR; Ameye L; Paesmans M; Bron D
    Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):264-8. PubMed ID: 26935576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.